The landscape of new drugs in lymphoma

被引：64

作者：

Younes, Anas ^{[1
]}

Ansell, Stephen ^{[2
]}

Fowler, Nathan ^{[3
]}

Wilson, Wyndham ^{[4
]}

de Vos, Sven ^{[5
]}

Seymour, John ^{[6
]}

Advani, Ranjana ^{[7
]}

Forero, Andres ^{[8
]}

Morschhauser, Franck ^{[9
]}

Kersten, Marie Jose ^{[10
,11
]}

Tobinai, Kensei ^{[12
]}

Zinzani, Pier Luigi ^{[13
]}

Zucca, Emanuele ^{[14
]}

Abramson, Jeremy ^{[15
]}

Vose, Julie ^{[16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Mayo Clin, Div Haematol, 200 1st St Sw, Rochester, MN 55905 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, 1515 Holcombe Blvd, Houston, TX 77030 USA

[4] NCI, Lymphoid Malignancies Branch, 9000 Rockville Pike, Bethesda, MD 20892 USA

[5] Ronald Reagan UCLA Med Ctr, Dept Med, Santa Monica, CA 90404 USA

[6] Peter MacCallum Canc Ctr, Dept Haematol, ABeckett St, East Melbourne, Vic 8006, Australia

[7] Stanford Univ, Canc Ctr, Div Oncol, 875 Blake Wilbur Dr, Stanford, CA 94305 USA

[8] Univ Alabama Birmingham, Sch Med, Div Haematol & Oncol, 1720 2nd Ave South,NP2540, Birmingham, AL 35294 USA

[9] Hop Claude Huriez, Dept Haematol, F-59037 Lille, France

[10] Acad Med Ctr, Dept Haematol, Amsterdam, Netherlands

[11] LYMMCARE, Amsterdam, Netherlands

[12] Natl Canc Ctr, Haematol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan

[13] Univ Bologna, Inst Haematol LeA Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[14] Osped San Giovanni Bellinzona, Oncol Inst Southern Switzerland, CH-6500 Bellinzona, Switzerland

[15] Massachusetts Gen Hosp, Canc Ctr, Yawkey Ctr Outpatient Care, Mailstop Yawkey 9A,32 Fruit St, Boston, MA 02114 USA

[16] UNMC Oncol Haematol Div, 987680 Nebraska Med Ctr, Omaha, NE 68198 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 06期

关键词：

NON-HODGKIN-LYMPHOMA; B-CELL LYMPHOMA; SINGLE-AGENT LENALIDOMIDE; BROMODOMAIN INHIBITOR OTX015; JAK-STAT PATHWAY; OPEN-LABEL; DOSE-ESCALATION; THERAPEUTIC STRATEGY; POLATUZUMAB VEDOTIN; ANTITUMOR-ACTIVITY;

D O I：

10.1038/nrclinonc.2016.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.

引用

页码：335 / 346

页数：12

共 106 条

[1]

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[2]

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) [J].

Advani, Ranjana ;

Lebmic, Daniel ;

Brunvand, Mark ;

Chen, Andy I. ;

Goy, Andre ;

Chang, Julie E. ;

Maeda, Lauren S. ;

Ho, William ;

Kahn, Robert ;

Lu, Dan ;

Su, Meng ;

Chu, Yu-Waye ;

Cheson, Bruce D. .

BLOOD, 2012, 120 (21)

[3]

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[4]

Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study [J].

Amorim, Sandy ;

Stathis, Anastasios ;

Gleeson, Mary ;

Iyengar, Sunil ;

Magarotto, Valeria ;

Leleu, Xavier ;

Morschhauser, Franck ;

Karlin, Lionel ;

Broussais, Florence ;

Rezai, Keyvan ;

Herait, Patrice ;

Kahatt, Carmen ;

Lokiec, Francois ;

Salles, Gilles ;

Facon, Thierry ;

Palumbo, Antonio ;

Cunningham, David ;

Zucca, Emanuele ;

Thieblemont, Catherine .

LANCET HAEMATOLOGY, 2016, 3 (04) :E196-E204

[5]

T-Cell Signaling Regulated by the Tec Family Kinase, Itk [J].

Andreotti, Amy H. ;

Schwartzberg, Pamela L. ;

Joseph, Raji E. ;

Berg, Leslie J. .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (07) :a002287

[6]

[Anonymous], 2015, BLOOD

[7]

[Anonymous], 2015, BLOOD

[8]

[Anonymous], ASCO M S 15

[9]

[Anonymous], ASCO M S15

[10]

[Anonymous], 2015, BLOOD, DOI DOI 10.1182/blood.V126.23.1491.1491

← 1 2 3 4 5 6 7 8 9 10 →